Not the full statistical plan. However it could be something along the lines like the snapshot at the end, taken from a trial design paper for a current study in FSGS called ClopiD4FSGS which can be found online. They disclose the futility threshold based on proteinuria and what will lead them to make a call on whether the trial is futile or not. That shows real transparency without biasing or affecting integrity of trial. You're right, no law that says DMX has to divulge the futility threshold they chose and I doubt 99% of investors or ASX would care. More a question of why wouldn't you disclose it if you're confident you can explain/defend it.
all a bit moot though as this futility interim was based on an surrogate which isn't the final endpoint anyway. that is GFR slope and I'd suggest this drug will stand or fall on what it does to that, not proteinuria.
- Forums
- ASX - By Stock
- DXB
- Ann: Dimerix Successfully Passes Efficacy Interim Analysis
Ann: Dimerix Successfully Passes Efficacy Interim Analysis, page-154
-
-
- There are more pages in this discussion • 126 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
51.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $280.6M |
Open | High | Low | Value | Volume |
51.5¢ | 54.5¢ | 51.0¢ | $1.715M | 3.301M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 365433 | 51.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
51.5¢ | 19658 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 348488 | 0.510 |
7 | 159577 | 0.505 |
9 | 326933 | 0.500 |
6 | 141020 | 0.495 |
8 | 79503 | 0.490 |
Price($) | Vol. | No. |
---|---|---|
0.520 | 4807 | 1 |
0.535 | 6099 | 1 |
0.540 | 230559 | 3 |
0.545 | 8075 | 2 |
0.550 | 19750 | 3 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online